

Vycor Medical, Inc. Patent Portfolio Expands

BOCA RATON, FL (July 25, 2011) – Vycor Medical, Inc. (“Vycor”) announces that its subsidiary, NovaVision, Inc., has received allowance for the issuance of two further patents. This will bring the total number of worldwide granted or issued patents held by the Vycor Group to 17, with a further 34 patents pending.

The first allowance for issuance is for China patent 98814262.7, supporting the core NovaVision VRT™ treatment of the transition zone which has already had patents granted in the US, Canada, and Europe.

The second allowance for issuance is US patent 29/351,089 which is a design patent for its innovative Head Mountable Display Visor goggles.

This announcement follows a previous announcement in May of the allowance for grant of patents for Vycor’s core neurosurgical VBAS device both in China, where it is in the process of getting SFDA approval for the sale of VBAS, and in Russia.

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (VYCO.BB) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective. Vycor’s innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, CE Marking and HPB licensing in Canada.

Vycor Medical’s subsidiary NovaVision, Inc. researches, develops and provides science-driven light-based neurostimulation therapy and other medical technologies that help restore sight to patients with neurological vision impairments. The company’s proprietary, Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injury. VRT has FDA 510(K) clearance with patents granted in the US, Canada, and Europe. NovaVision also provides a device that aids in the early identification of visual field deficits: the Head Mounted Perimeter (HMP™) - a portable and ADA-compliant instrument to aid in the detection and measurement of visual field deficits even in bed-ridden patients.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

###